Breast carcinoma is highly heterogeneous, with triple negative breast cancer (TNBC) being the most aggressive that does not respond well to canonical hormonal or targeted therapeutic strategies due to the lack of surface receptors such as estrogen receptor (ER), progesterone receptor (PR) and human epithelial receptor 2 (HER2)2, 3. Here, ESR1 is linked to triple-negative breast carcinoma.